The European Society of Cardiology (ESC) Heart Failure (HF) congress took place in Prague, Czech Republic from 20-23 May 2023. Here are our top highlights from ESC-HF.
PARAGLIDE-HF (NCT03988634)compared outcomes using sacubitril/valsartan versus valsartan alone in HF with preserved ejection fraction (HFpEF) and worsening HF. Investigators compared proportional change in amino terminal pro–B-type natriuretic peptide (NT-proBNP) between the groups. Patients who received sacubitril/valsartan (n=233) achieved greater reductions in NT-proBNP levels than patients who received valsartan alone (n=233). Sacubitril/valsartan reduced worsening renal function, but increased symptomatic hypotension1.
DAPA MODA (NCT04707352) assessed the effects of dapagliflozin on cardiac remodeling over a period of six months. Investigators enrolled 162 patients with stable chronic HF, regardless of ejection fraction (EF). At 180 day follow-up, investigators noted significant...
Log in to get full access to ESC HF 2023 conference highlights.
